Trial results for a study investigating ALK resistance mechanisms in Non-Small Cell Lung Cancer (NSCLC) were posted on ClinicalTrials.gov on 2025-10-02, with 62 participants enrolled.
Background
ALK-positive lung cancer is a subtype of lung cancer characterized by a change in the ALK (anaplastic lymphoma kinase) gene. While several drugs exist to slow cancer growth in these patients, resistance often develops over time as the cancer evolves new mutations, causing therapies to lose effectiveness. Understanding the range of these resistance mutations is crucial for identifying potential new treatment strategies.
Trial design
This completed study enrolled 62 participants with Non-Small Cell Lung Cancer. The study aimed to assess, characterize, and evaluate patients with ALK resistance, focusing on understanding the range of mutations that develop when ALK-positive lung cancers evolve ways to avoid therapies.
Key results
The study reported several key measurements regarding ALK fusions and resistance mechanisms in patients with ALK-positive NSCLC and progression:
- The prevalence of ALK fusion was observed in 27 Participants.
- The ALK fusion allelic frequency had a median of 2.6 percentage of the ALK fusion (Full Range).
- The overall prevalence of ALK resistance mechanisms among patients with the ALK fusion was found in 17 Participants.
- Specific types of resistance mechanisms included:
- One or More Secondary ALK Kinase Domain Resistance Mutations in 8 Participants.
- Both ALK Resistance Mutations and Bypass Resistance in 6 Participants.
- Bypass Track Resistance in 3 Participants.
- 49 Participants changed treatment for NSCLC.
- Regarding treatment outcome, 7 Participants showed a >50% Reduction of ALK Fusion Allele Frequency.
What this means
These results provide valuable insights into the landscape of ALK resistance mechanisms in patients with ALK-positive Non-Small Cell Lung Cancer who experience disease progression. The identification of specific resistance types, such as secondary ALK kinase domain mutations and bypass resistance, helps characterize how these cancers evolve. This understanding is critical for guiding subsequent treatment decisions and for the development of new targeted therapies designed to overcome these specific resistance pathways. The observed reduction in ALK fusion allele frequency in some patients following treatment changes underscores the potential for personalized approaches based on resistance profiling.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT03833934, titled "Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance", were posted on 2025-10-02 on clinicaltrials.gov.